Multicenter, randomized, double‐blinded, placebo‐controlled study of rabacfosadine in dogs with lymphoma

Multicenter, randomized, double‐blinded, placebo‐controlled study of rabacfosadine in dogs with lymphoma

Abstract Background Rabacfosadine (RAB, Tanovea‐CA1) is a novel chemotherapy agent conditionally approved for the treatment of lymphoma in dogs. Hypothesis/Objectives To determine the efficacy and safety of RAB in dogs with lymphoma. Animals One hundred and fifty‐eight client‐owned dogs with naïve o...

Full description

Bibliographic Details
Main Authors: Kristen M. Weishaar, Zachary M. Wright, Mona P. Rosenberg, Gerald S. Post, Jennifer A. McDaniel, Craig A. Clifford, Brenda S. Phillips, Philip J. Bergman, Elissa K. Randall, Anne C. Avery, Douglas H. Thamm, Abigail A. Christman Hull, Cathy M. Gust, Ann R. Donoghue
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Journal of Veterinary Internal Medicine
Subjects:
canine
chemotherapy
multicentric
neoplasia
Online Access:https://doi.org/10.1111/jvim.16341

Internet

https://doi.org/10.1111/jvim.16341

Similar Items